All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 21, 2023
Home » Topics » Newco news

Newco news
Newco news RSS Feed RSS

Digital heart illustration

Egnite aims to spark change in structural heart disease care with new predictive suite

May 12, 2021
By Annette Boyle
No Comments
Egnite Inc. emerged from stealth mode in February 2021 with the goal of combining data analytics and digital health technology to illuminate and solve persistent issues in the diagnosis and treatment of structural heart disease. Three months later, it has added artificial intelligence (AI) to its flagship solution, Cardiocare, to drive better diagnosis of aortic stenosis and help physicians predict patient outcomes.
Read More
Cancer research illustration
Newco news

Adcendo raises $61M series A round to advance uPARAP-targeting ADC candidate

May 3, 2021
By Nuala Moran
No Comments
LONDON – In what is claimed as the largest series A for a Danish biotech, Adcendo ApS has raised €51 million (US$61.3 million) to take forward antibody-drug conjugate (ADC) drugs aimed at proprietary targets that are involved in cellular recycling processes.
Read More
Hand holding money plant
Newco news

Stuart Therapeutics raise $11M to back topical dry eye disease candidate

April 27, 2021
By Michael Fitzhugh
No Comments
Stuart Therapeutics Inc., a company developing peptide therapeutics for ophthalmic disease, has completed an $11 million series A financing led by Infocus Capital Partners, an ophthalmology-focused life sciences venture capital fund, with significant participation by the Wisconsin Alumni Research Foundation, Mimo Capital and Biobrit.
Read More
Imageens concept art and logo

Imageens raises $1.4M to launch its first AI and predictive biomarker software for cardiology

April 23, 2021
By Bernard Banga
No Comments
PARIS – Imageens SAS just raised a $1.4 million seed round to develop its two artificial intelligence (AI) systems in the field of medical imaging in Europe. Its first solution Artfun+, an AI software application, makes it possible to anticipate cardiovascular pathology thanks to new prognostic biomarkers. Its second product is Label, an algorithm which automatically classifies and assesses medical imaging data.
Read More
Digital cancer cells illustration
Newco news

OS Therapies lands $6M series A to support osteosarcoma program, drug conjugate platform

April 20, 2021
By Michael Fitzhugh
No Comments
OS Therapies LLC, the developer of a listeria-based cancer vaccine to prevent metastasis and increase overall survival in young people with osteosarcoma, has closed on a $6 million series A financing led by Noble Capital Markets and Tichenor Ventures. The funds will help the company advance its lead candidate, OST-HER2, into a phase IIb trial this year with hopes of a potential FDA filing by in 2022.
Read More
Cancer cells under magnifying glass
Newco news

Nammi steps out with two cancer candidates

April 9, 2021
By Lee Landenberger
No Comments
In science there are often too many choices to make. Nammi Therapeutics Inc.’s CEO, David Stover, told BioWorld that he makes narrowing therapeutic options a core company principle. The redundancy of immune regulatory pathways in cancer treatments is a case in point.
Read More
Health professional reviewing digital health data

Xenter debuts with focus on health data, wireless technologies

April 8, 2021
By Meg Bryant
No Comments
Xenter Inc. has officially launched, positioning itself as the first startup device/data/drug med-tech company. The company is developing wireless solutions for interventional cardiology, interventional radiology and neurointerventional radiology.
Read More
Red rocket launch button on keyboard

Xenter debuts with focus on health data, wireless technologies

April 7, 2021
By Meg Bryant
No Comments
Xenter Inc. has officially launched, positioning itself as the first startup device/data/drug med-tech company. The company is developing wireless solutions for interventional cardiology, interventional radiology and neurointerventional radiology. The company’s goal is to take the medical devices that have been used most ubiquitously throughout medicine, one by one, and replace them with smart technologies that incorporate such things as software, sensors and signals technologies.
Read More
Human NK cell
Newco news

Shoreline Biosciences raises $43M to advance allogenic NK and macrophage cell therapies

April 7, 2021
By Michael Fitzhugh
No Comments
Shoreline Biosciences Inc., a San Diego-based company developing allogenic natural killer and macrophage cellular therapies for cancer and other diseases, has raised $43 million in a financing led by Boxer Capital.
Read More
Red rocket launch button on keyboard
Newco news

U.S.-China cross-border biopharma launched to target autoimmune diseases

March 30, 2021
By Sergio Held
No Comments
Zenas Biopharma LLC launched on March 23 as a U.S. funded cross-border biotech company targeting autoimmune diseases in China. The company, headquartered in Miromar Lakes, Fla., is founded and funded by Tellus Bioventures LLC and Fairmount Funds Management LLC.
Read More
Previous 1 2 … 14 15 16 17 18 19 20 21 22 … 36 37 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 20, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 20, 2022.
  • Woman with headache

    Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

    BioWorld
    Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...
  • Lungs

    Affibody in $637M respiratory disease deal with Chiesi

    BioWorld
    Chiesi Farmaceutici SpA has agreed to pay Affibody AB up to $214 million in a collaboration and licensing agreement to develop an inhaled treatment for...
  • Women handshake with virology graphics

    Modex codex may read out new story in EBV with Merck vaccine pact worth $922M-plus

    BioWorld
    Another step forward in the quest for an Epstein-Barr virus (EBV) vaccine took the form of Merck & Co. Inc.’s deal with Modex Therapeutics Inc., owned by Opko...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing